Table 1

The effect of baseline A1C and diabetes duration on the fall in A1C with OAD therapy

Follow-up time (weeks)Comparisons (n)Change in A1C (%) for every 1% higher baseline A1C (95% CI)*Change in A1C (%) for every 1 year greater diabetes duration (95% CI)**
12500.01 (−0.2 to 0.2)−0.1 (−0.13 to −0.002)
13–1857−0.2 (−0.4 to −0.05)0.03 (−0.01 to −0.1)
19–2447−0.3 (−0.6 to −0.1)§0.08 (0.01–0.15)
25–3921−0.5 (−0.9 to −0.1)−0.03 (−0.1 to 0.1)
  • Estimates are derived from a meta-regression analysis that controlled for:

  • *drug class, drug dose, and baseline A1C;

  • **drug class, drug dose, baseline A1C, and duration of diabetes.

  • P < 0.05;

  • P < 0.02;

  • §P < 0.01;

  • P < 0.03.